Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date July 07, 2017 · Filed July 11, 2017
Section 16 reporting ended · disclosed 2017-07-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 183,116 |
Reported balance
After 2017-07-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-07-07 · Tax withholding · Disposed 3,288 · Balance 183,116 F1: Due to an administrative calculation error, the Form 4 filed on January 6, 2017, underreported the reporting person's ownership by 1 share. |
| Common shares without par valueSEC Table I · non-derivative | IndirectFamily Trust | 446,178 |
Reported balance
Holding disclosure · report date 2017-07-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 446,178 |
Filing footnotes · ownership attribution and instrument terms
F1: Due to an administrative calculation error, the Form 4 filed on January 6, 2017, underreported the reporting person's ownership by 1 share.
ST JUDE MEDICAL, LLC
Report date January 04, 2017 · Filed January 06, 2017
Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 1
1 source rowRow 1 · 2017-01-04 · Disposition to issuer · Disposed 46,779 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. |
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 0 |
Reported balance
After 2017-01-04 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-01-04 · Disposition to issuer · Disposed 19,618 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. F5: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.59 · Expires 2017-12-14 | IndirectFamily Trust | 0 |
Reported balance
After 2017-01-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-04 · Disposition to issuer · Disposed 182,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.65 · Expires 2018-12-14 | IndirectFamily Trust | 0 |
Reported balance
After 2017-01-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-01-04 · Disposition to issuer · Disposed 204,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.96 · Expires 2019-12-12 | IndirectFamily Trust | 0 |
Reported balance
After 2017-01-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-01-04 · Disposition to issuer · Disposed 300,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2020-12-10 | IndirectFamily Trust | 0 |
Reported balance
After 2017-01-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-01-04 · Disposition to issuer · Disposed 183,750 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-12-10 | IndirectFamily Trust | 0 |
Reported balance
After 2017-01-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-01-04 · Disposition to issuer · Disposed 74,570 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.08 · Expires 2022-12-08 | IndirectFamily Trust | 0 |
Reported balance
After 2017-01-04 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2017-01-04 · Disposition to issuer · Disposed 36,148 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2020-12-10 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-01-04 · Disposition to issuer · Disposed 61,250 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-12-10 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-01-04 · Disposition to issuer · Disposed 74,570 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.08 · Expires 2016-12-08 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-01-04 · Disposition to issuer · Disposed 108,444 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.62 · Expires 2023-12-07 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2017-01-04 · Disposition to issuer · Disposed 348,888 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-01-04 · Disposition to issuer · Disposed 4,474 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2017-01-04 · Disposition to issuer · Disposed 8,214 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2017-01-04 · Disposition to issuer · Disposed 27,789 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
F3: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.
F5: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2017 Filed Jul 11, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,288 | $48.44 | $159,270.72 |
DisclosureSEC source: 0001179110-17-010300 · edgar.xml · nonDerivative · entry 1 ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovas. & Neuromod. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,116 F1 · balance_after: Due to an administrative calculation error, the Form 4 filed on January 6, 2017, underreported the reporting person's ownership by 1 share. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 27,789 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 15 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,789 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 348,888 | Not disclosed Strike: $61.62 | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 14 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 348,888 shares Expires 2023-12-07 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 8,214 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 13 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,214 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 36,148 | Not disclosed Strike: $69.08 | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 12 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 0 Underlying: Common Stock · 36,148 shares Expires 2022-12-08 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 108,444 | Not disclosed Strike: $69.08 | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 11 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,444 shares Expires 2016-12-08 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 4,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 10 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,474 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 74,570 | Not disclosed Strike: $59.41 | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 9 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,570 shares Expires 2021-12-10 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 74,570 | Not disclosed Strike: $59.41 | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 8 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 0 Underlying: Common Stock · 74,570 shares Expires 2021-12-10 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 61,250 | Not disclosed Strike: $35.27 | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 7 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,250 shares Expires 2020-12-10 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 183,750 | Not disclosed Strike: $35.27 | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 6 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 0 Underlying: Common Stock · 183,750 shares Expires 2020-12-10 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 300,000 | Not disclosed Strike: $34.96 | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 5 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2019-12-12 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 204,000 | Not disclosed Strike: $41.65 | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 4 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 0 Underlying: Common Stock · 204,000 shares Expires 2018-12-14 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 182,000 | Not disclosed Strike: $38.59 | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · derivative · entry 3 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 0 Underlying: Common Stock · 182,000 shares Expires 2017-12-14 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F5 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerCommon Stock | 19,618 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · nonDerivative · entry 2 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. F5 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerCommon Stock | 46,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000618 · edgar.xml · nonDerivative · entry 1 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 545,573 | Not disclosed Strike: $29.56 | Not disclosed |
DisclosureSEC source: 0001104659-17-001247 · a4.xml · derivative · entry 8 ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,573 Underlying: Common shares without par value · 545,573 shares Expires 2023-12-07 F6 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F6 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F9 · derivative.exercise_date: 181,857 options are scheduled to vest on December 17, 2017, 181,857 options are scheduled to vest on December 17, 2018 and 181,859 options are scheduled to vest on January 4, 2019. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 150,737 | Not disclosed Strike: $33.14 | Not disclosed |
DisclosureSEC source: 0001104659-17-001247 · a4.xml · derivative · entry 7 ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,737 Underlying: Common shares without par value · 150,737 shares Expires 2022-12-08 F6 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F6 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F8 · derivative.exercise_date: 75,368 options are scheduled to vest on December 17, 2017 and 75,369 options are scheduled to vest on December 17, 2018. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 77,739 | Not disclosed Strike: $28.50 | Not disclosed |
DisclosureSEC source: 0001104659-17-001247 · a4.xml · derivative · entry 6 ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,739 Underlying: Common shares without par value · 77,739 shares Expires 2021-12-10 F6 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F6 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F7 · derivative.exercise_date: These options are scheduled to vest on December 17, 2017. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 429,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-001247 · a4.xml · nonDerivative · entry 5 ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod. 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 632,581 F2 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each vested St. Jude Medical stock option was deemed exercised pursuant to a cashless exercise and deemed settled by issuance of a number of St. Jude Medical shares equal to the difference (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (a) the number of St. Jude Medical common shares subject to such surrendered St. Jude Medical option as of immediately prior to the First Effective Time minus (b) the number of whole and partial (computed to the nearest four decimal places) St. Jude Medical common shares that, when multiplied by $80.82 (the closing price of a St. Jude Medical common share on January 4, 2017), is equal to the aggregate exercise price of such surrendered St. Jude Medical option. (Continued in footnote 3). F3 · price: Such St. Jude Medical common shares were then canceled and converted into the right to receive the merger consideration with respect to each St. Jude Medical common share issued in respect of the stock option, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 17,083 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-001247 · a4.xml · nonDerivative · entry 4 ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod. 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 203,486 F1 · price: On January 4, 2017, Abbott Laboratories ("Abbott") acquired St. Jude Medical, Inc. ("St. Jude Medical") pursuant to the Agreement and Plan of Merger by and among Abbott, St. Jude Medical, Vault Merger Sub, Inc. and Vault Merger Sub, LLC dated as of April 27, 2016 (the "Merger Agreement"). Upon the First Effective Time (as defined in the Merger Agreement), each outstanding St. Jude Medical common share (other than certain shares identified in the Merger Agreement) was converted into the right to receive (a) $46.75 in cash, without interest, and (b) 0.8708 common shares of Abbott. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 84,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-001247 · a4.xml · nonDerivative · entry 3 ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,403 F4 · shares: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical restricted stock unit award was canceled and converted into a restricted stock unit award, with substantially the same terms and conditions as were applicable to such St. Jude Medical award (except that, subject to the holder's continued employment, the award will fully vest to the extent unvested on the second anniversary of the First Effective Time), that is settleable with respect to a number of Abbott common shares equal to the product (rounded to the nearest whole share) of (a) the number of St. Jude Medical shares subject to such award multiplied by (b) 2.0850 (the "Stock Award Exchange Ratio"). F5 · shares: 37,204 restricted stock units are scheduled to vest on December 17, 2017 and will be settled promptly thereafter, 27,876 restricted stock units are scheduled to vest on December 17, 2018 and will be settled promptly thereafter, and 19,314 restricted stock units are scheduled to vest on January 4, 2019 and will be settled December 17, 2019. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 61,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-001247 · a4.xml · nonDerivative · entry 2 ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,010 F2 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each vested St. Jude Medical stock option was deemed exercised pursuant to a cashless exercise and deemed settled by issuance of a number of St. Jude Medical shares equal to the difference (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (a) the number of St. Jude Medical common shares subject to such surrendered St. Jude Medical option as of immediately prior to the First Effective Time minus (b) the number of whole and partial (computed to the nearest four decimal places) St. Jude Medical common shares that, when multiplied by $80.82 (the closing price of a St. Jude Medical common share on January 4, 2017), is equal to the aggregate exercise price of such surrendered St. Jude Medical option. (Continued in footnote 3). F3 · price: Such St. Jude Medical common shares were then canceled and converted into the right to receive the merger consideration with respect to each St. Jude Medical common share issued in respect of the stock option, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 40,735 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-001247 · a4.xml · nonDerivative · entry 1 ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,735 F1 · price: On January 4, 2017, Abbott Laboratories ("Abbott") acquired St. Jude Medical, Inc. ("St. Jude Medical") pursuant to the Agreement and Plan of Merger by and among Abbott, St. Jude Medical, Vault Merger Sub, Inc. and Vault Merger Sub, LLC dated as of April 27, 2016 (the "Merger Agreement"). Upon the First Effective Time (as defined in the Merger Agreement), each outstanding St. Jude Medical common share (other than certain shares identified in the Merger Agreement) was converted into the right to receive (a) $46.75 in cash, without interest, and (b) 0.8708 common shares of Abbott. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock Units · Derivative | 9,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · derivative · entry 13 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,789 Underlying: Common Stock · 37,052 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock Units · Derivative | 4,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · derivative · entry 12 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,214 Underlying: Common Stock · 12,321 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock Units · Derivative | 4,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · derivative · entry 11 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,474 Underlying: Common Stock · 8,948 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock Units · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · derivative · entry 10 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Tax withholdingCommon Stock | 3,897 | $79.20 | $308,642.40 |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · nonDerivative · entry 8 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,779 F5 · shares: 9,263 shares of restricted stock vested on December 17, 2016. 3,897 shares were used to pay taxes and 5,366 shares were released. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 9,263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · nonDerivative · entry 7 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Tax withholdingCommon Stock | 1,730 | $79.20 | $137,016.00 |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · nonDerivative · entry 6 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,413 F4 · shares: 4,107 shares of restricted stock vested on December 17, 2016. 1,730 shares were used to pay taxes and 2,377 shares were released. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 4,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · nonDerivative · entry 5 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Tax withholdingCommon Stock | 1,886 | $79.20 | $149,371.20 |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · nonDerivative · entry 4 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,036 F3 · shares: 4,474 shares of restricted stock vested on December 17, 2016. 1,886 shares were used to pay taxes and 2,588 shares were released. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 4,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · nonDerivative · entry 3 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Tax withholdingCommon Stock | 3,374 | $79.20 | $267,220.80 |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · nonDerivative · entry 2 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,448 F2 · shares: 8,000 shares of restricted stock vested on December 17, 2016. 3,374 shares were used to pay taxes and 4,626 shares were released. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:15 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 8,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033313 · edgar.xml · nonDerivative · entry 1 ROUSSEAU MICHAEL T · CIK 0001233677 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $30.58 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 6 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2016-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested at the time of filing. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 36,148 | $0.00 Strike: $69.08 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 18 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 36,148 Underlying: Common Stock · 36,148 shares Expires 2022-12-08 F5 · derivative.exercise_date: The option shares vest 25% on each of the first four anniversary dates of the date of the grant beginning on the date shown. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 36,148 | $0.00 Strike: $69.08 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 17 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,444 Underlying: Common Stock · 144,592 shares Expires 2022-12-08 F5 · derivative.exercise_date: The option shares vest 25% on each of the first four anniversary dates of the date of the grant beginning on the date shown. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 74,570 | $0.00 Strike: $59.41 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 16 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 74,570 Underlying: Common Stock · 74,570 shares Expires 2021-12-10 F5 · derivative.exercise_date: The option shares vest 25% on each of the first four anniversary dates of the date of the grant beginning on the date shown. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 74,570 | $0.00 Strike: $59.41 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 15 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,570 Underlying: Common Stock · 149,140 shares Expires 2021-12-10 F5 · derivative.exercise_date: The option shares vest 25% on each of the first four anniversary dates of the date of the grant beginning on the date shown. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 183,750 | $0.00 Strike: $35.27 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 14 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 183,750 Underlying: Common Stock · 183,750 shares Expires 2020-12-10 F5 · derivative.exercise_date: The option shares vest 25% on each of the first four anniversary dates of the date of the grant beginning on the date shown. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 183,750 | $0.00 Strike: $35.27 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 13 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,250 Underlying: Common Stock · 245,000 shares Expires 2020-12-10 F5 · derivative.exercise_date: The option shares vest 25% on each of the first four anniversary dates of the date of the grant beginning on the date shown. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $34.96 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 12 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2019-12-12 F4 · derivative.exercise_date: Fully vested at the time of filing. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $34.96 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 11 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2019-12-12 F4 · derivative.exercise_date: Fully vested at the time of filing. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 204,000 | $0.00 Strike: $41.65 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 10 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 204,000 Underlying: Common Stock · 204,000 shares Expires 2017-12-14 F4 · derivative.exercise_date: Fully vested at the time of filing. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 204,000 | $0.00 Strike: $41.65 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 9 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 204,000 shares Expires 2018-12-14 F4 · derivative.exercise_date: Fully vested at the time of filing. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 182,000 | $0.00 Strike: $30.59 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 8 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 182,000 Underlying: Common Stock · 182,000 shares Expires 2017-12-14 F4 · derivative.exercise_date: Fully vested at the time of filing. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 182,000 | $0.00 Strike: $30.59 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 7 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 182,000 shares Expires 2017-12-14 F4 · derivative.exercise_date: Fully vested at the time of filing. Read SEC document |
| October 18, 2016 Filed Dec 19, 2016 16:10 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | GiftStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $30.58 | $0.00 |
DisclosureSEC source: 0001179110-16-033192 · edgar.xml · derivative · entry 5 ROUSSEAU MICHAEL T · CIK 0001233677 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2016-12-15 F4 · derivative.exercise_date: Fully vested at the time of filing. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.